Skip to content

Quantum biosensing for skin cancer - NV-diamond magnetometry and nanothermometry for high-precision tumor margin mapping and microenvironment analysis at single-cell resolution

FieldValue
JournalIranian Journal of Burns and Wound Research
Published2026-08-01
AuthorsMasiha Mobayen, Ali Aghaahmadi, Amirsalar Amirinezhad, Komeil Babaei Velni, Alireza Feizkhah
DOI10.66224/ijbwr.2.2.63

NV-diamond sensing offers a preclinical route to label-free tumor-margin mapping at single-cell resolution through combined thermometry and magnetometry. The review cites a measured room-temperature zero-field splitting coefficient of -74 kHz/K and identifies a required thermal sensitivity on the order of mK/√Hz. These platform results do not establish clinical performance in skin cancer, and no in vivo human trial has evaluated NV-diamond sensors.

PubMed, Scopus, and Web of Science were searched from January 2016 through June 2026. The authors used a narrative review to synthesize NV-diamond sensing in dermatological oncology. Search terms covered nitrogen-vacancy centers, quantum biosensing, dermatological oncology, and single-cell imaging.

The evidence comes from cited studies rather than new clinical measurements. Human evidence is limited to ex vivo formalin-fixed, paraffin-embedded tumor tissue and human cancer cell lines in vitro. True in vivo studies cited in the review involve mice and C. elegans. The proposed skin-cancer margin application remains a development target, not an established clinical procedure.

An NV center consists of a substitutional nitrogen atom next to a vacancy in the diamond lattice. The tetrahedral lattice permits four crystallographic orientations. Its negatively charged, neutral, and positively charged states have different sensing behavior, and the negatively charged state is the most studied for practical use.

Optical detection uses 532 nm excitation and collects 637 nm fluorescence. Applied microwaves drive spin transitions and produce fluorescence dips in the optically detected magnetic resonance spectrum. Without an applied magnetic field, the zero-field splitting D is 2.87 GHz. The electron gyromagnetic ratio is 28 MHz/mT, linking resonance shifts to magnetic field.

Temperature alters D through lattice expansion and electron-phonon coupling. A cited measurement gives dD/dT of about -74 kHz/K in the room-temperature linear regime. ODMR frequency shifts therefore provide a temperature estimate without relying on fluorescence intensity. T1 relaxometry provides a separate readout of local magnetic noise from unpaired electrons.

Hypermetabolic cancer cells shift toward aerobic glycolysis through the Warburg effect. The review connects this metabolism to localized thermogenesis and subcellular temperature gradients. Accurate mapping requires sub-micrometer spatial resolution and thermal sensitivity on the order of mK/√Hz.

Conventional infrared thermography is limited by optical diffraction to micrometer-scale spatial resolution. Contact probes can disturb the cellular thermal environment. Organic fluorescent thermometers can respond to pH, ionic strength, and molecular crowding, and can bleach or diffuse.

NV thermometry tracks ODMR frequency shifts from fluorescent nanodiamonds taken up by cancer cells through endocytosis in cited work. Confocal scanning or wide-field imaging reconstructs temperature at each coordinate from the local frequency shift. A prior hybrid nanodiamond study mapped thermal conductivity at less than one-micron resolution. That result concerned thermal-conductivity mapping, not skin-cancer margin classification. Benign inflammation can produce similar thermal changes, so heat alone is not a specific tumor marker.

NV magnetometry reads local magnetic fields through ODMR Zeeman shifts or spin-relaxation rates. Proposed skin-tumor targets include iron accumulation, magnetic nanoparticles, and free-radical activity. Widefield quantum magnetic microscopy has resolved weak fields around individual cells at sensitivities from microtesla to picotesla. SPION labeling can mark cells, and neural networks trained on simulated dipoles can reconstruct labeling at single-cell resolution.

T1 relaxometry measures magnetic noise from unpaired electrons and can report ROS activity. The review cites detection of a few H2O2 molecules with self-reporting fluorescent nanodiamond sensors. That molecular result did not occur during surgery. Prior work also distinguished radical production from polarized M1 and M2 macrophages. Label-free NMR relaxometry separated MCF7 and HeLa cells using intracellular water proton T1. Those findings came from breast and cervical cancer models and require confirmation in skin-derived tumors.

The review also cites magnetometry of FFPE human tumor tissue and surface-engineered nanodiamonds in B16F10 melanoma cells. Neither result establishes in vivo human skin-cancer sensing.

Three delivery routes are proposed for skin tumors. Intralesional or peritumoral injection places functionalized nanodiamonds in the tumor bed and surrounding margins. Topical delivery may use microneedles or permeation enhancers for superficial lesions. Intravenous delivery may target deeper or metastatic disease through antibodies, peptides, and the enhanced permeability and retention effect.

The proposed intraoperative instrument is a handheld fiber-optic probe using 532 nm green laser excitation. Spin-dependent fluorescence would be analyzed during surgery to form a live map. Antibody-functionalized fluorescent nanodiamonds would bind overexpressed receptors on cancer cells. Dual-mode sensing separates metabolic heat from paramagnetic and radical signals. FFPE immunomagnetic microscopy could provide a second check using molecular targets. Integration with 40 nm CMOS single-photon avalanche diode arrays is presented as a route toward scalable readout. The result remains a proposed single-cell boundary map, not a clinically validated classifier.

Mohs micrographic surgery remains the review’s gold standard for high-risk cutaneous malignancies. The reported cure rate exceeds 99% for many primary tumors, but the method requires extensive histological processing. Frozen section concordance with permanent pathology remains imperfect.

MethodRole described in the reviewMain limitation stated in the review
Mohs micrographic surgeryMargin monitoring for high-risk skin cancerTime-consuming processing and extensive histology
Frozen sectionIntraoperative margin analysisSampling errors and imperfect diagnostic concordance
Optical coherence tomographyLabel-free optical imagingInsufficient single-cell lateral resolution and surgical artifacts
Raman spectroscopyLabel-free chemical imagingToo slow for real-time comprehensive margin assessment
NV-diamond sensingProposed thermal and magnetic mappingPreclinical evidence only, with no in vivo human trial

Prior quantum work imaged large tissue sections in a few minutes using spectrum demodulation. Sparse sampling and deep learning can reduce acquisition burden. Neither approach has established intraoperative accuracy in skin cancer.

Translational limits and engineering needs

Section titled “Translational limits and engineering needs”

No in vivo human clinical trial has evaluated NV-diamond sensors. Before human use, studies must establish safety, biocompatibility, biodistribution, clearance, and long-term biological fate. Hydrodynamic size mainly influences biodistribution, while long-term accumulation and clearance remain poorly characterized.

Dense stroma limits passive tumor penetration. Functionalization can improve uptake and penetration, but targeting must survive immune clearance. Current systems rely on bulky lasers, microwave antennas, calibration routines, and stable spin states. Thermal and mechanical instability can impair quantum-state control. Tissue scattering, autofluorescence, attenuation, and decoherence limit signal recovery. Signal-to-noise remains a central constraint.

Skin adds specific confounders. Severe actinic damage, biopsy-related fibrosis, and localized erythema can change thermal conductivity. Necrotic cores and slow-dividing margins may lack a hypermetabolic signature and cause false-negative assessment. Dual-mode studies must test keratinocytes and melanocytes because keratin and melanin may alter thermal and mechanical profiles.

Material qualification must address four NV orientations, charge-state behavior, hydrodynamic size, and surface chemistry. Handheld probes, chip-based microwave platforms, automated analysis, and AI-assisted classification remain development targets. Multicenter validation and scalable diamond manufacturing are required before routine use. The immediate engineering target is a validated probe that preserves NV readout during injection, illumination, and tissue scattering.

The paper’s device class needs NV-active diamond for intracellular thermometry, magnetometry, radical sensing, and surface-functionalized targeting. The diamond materials catalog includes single-crystal and polycrystalline diamond grown by MPCVD. 6CCVD’s engineering support can help define a custom geometry and material specification, although NV concentration and surface chemistry still need separate qualification.

View Original Abstract

Accurate delineation of tumor margins is important to successful surgical therapy of skin cancer, but existing gold-standard procedures, such as frozen section histopathology, are generally time-consuming and prone to sampling errors. In this narrative review, we explore the new paradigm of quantum biosensing, with an emphasis on the use of nitrogen-vacancy (NV) centers in diamond for advanced dermatological cancer. We review in detail the quantum features of NV defects that enable high-sensitivity, non-invasive sensing at ambient temperature. Specifically, we examine two main modalities: quantum nanothermometry, which senses the localized thermal fingerprints of hypermetabolic malignant cells; and NV-magnetometry, which maps the weak magnetic fields generated by iron buildup and free radicals in the tumor microenvironment. NV-diamond sensors can combine several modalities, enabling visualization of tumor margins at single-cell resolution and providing metabolic feedback in real-time, thus overcoming the limitations of traditional optical imaging methods, such as optical coherence tomography (OCT) or dermoscopy. This paper also discusses the technical hurdles in converting quantum sensing from the laboratory to the clinic, including issues of signal-to-noise ratio, biocompatibility, and device downsizing. Ultimately, we argue that while currently in the preclinical stage, quantum biosensing represents an exciting new frontier that holds the potential to significantly reduce recurrence rates and enhance patient outcomes by providing ultra-precise and label-free tumor mapping in the future.